ASPHALION’s Post

The traditional model of #clinicaltrials, while essential, often faces challenges in representing diverse patient populations and real-world scenarios. Recent advancements highlighted in an article published in NEJM Evidence emphasize the potential of #RWD to bridge these gaps. In this interview with Neal Meropol, Vice President of Research Oncology at Flatiron Health, we explore how these data-driven approaches are transforming #oncology trials, improving #patientoutcomes, and addressing disparities in health care. Read at The Evidence Base® #heor #healtheconomics #outcomesresearch #rwe #realworldevidence #realworlddata #regulation #regulatoryaffairs #healthdata #healthequity #healthpolicy

In this interview, Dr. Meropol speaks to access to oncology clinical trials, representation in clinical trials, and technology in clinical trials. Timely topics for the healthcare industry. I encourage you to give this a read!

Thanks to the 21st Century Cures Act and healthcare technology advances, #RWD is recognized as vital for understanding diseases and improving patient care. Understanding the quality of #RWD is essential to generating confidence in the #RWE resulting from its use. Multiple dimensions of quality must be assessed when making a fit-for-use determination—this new study, published in American Society of Clinical Oncology (ASCO)'s JCO Clinical Cancer Informatics, summarizes guidance around data quality from key regulatory and policy bodies, providing a framework for evaluating quality across multiple dimensions. Researchers aim to create transparency in how data quality can be assessed in scaled, EHR-based datasets. Visit our website to learn more and for a link to the full publication: https://lnkd.in/eEcQhc2S

Clinical trials need to be representative if we expect the results to be applicable to ALL cancer patients. Let's double down to help address this imperative by carefully designing trials that optimize patient access. Let's all commit to taking a data-driven approach to defining eligibility criteria, and reducing site burden by focusing data collection on only those elements absolutely critical to study objectives!

Last year's Advanced Research Projects Agency for Health (ARPA-H) Dash to Accelerate Health Outcomes challenged researchers and health advocates to submit their ideas to transform U.S. health within the next 20 years. The winner of that competition, Prosetta Biosciences Inc, is pushing for results much earlier than that. Their winning entry was titled, One Drug for All Cancers. Since the ARPA-H Dash, they have worked with the National Cancer Institute (NCI) to test their cancer therapeutic, PAV-541 and report groundbreaking results. They are now looking to move into FDA Phase I clinical trials in less than 12 months. Read their results and learn more about their journey below. #Bioscience #CancerResearch #Funding #Results #Therapeutic #PAV541 #STEM #Health #HealthOutcomes

The demand for #RWD on patients with cancer in Europe and Japan is increasing, particularly as many regulatory and #HTA bodies have stated a clear preference for local data in guidance on #RWE. At Flatiron Health, we're addressing this gap by now having EHR-derived data from the UK, Germany, and Japan. Hear Blythe Adamson, PhD, MPH, Head of Outcomes Research & Evidence Generation, share how Flatiron is filling critical evidence generation gaps with global oncology #realworlddata.

Georgi Nalbantov, PhD, Head of Data Science at CHILDISH.AI explores in a scientific study the impact of cardiac comorbidity on Radiation-Induced Lung Toxicity (RILT) in lung cancer patients. 📊 Key Insights: 28.9% of patients with cardiac comorbidity developed RILT 2.58x higher odds of RILT The predictive model achieves AUC 0.72 (training) and 0.67 (validation) Empower your healthcare decisions with advanced #AIexpertise! Dive deeper into our portfolio of impactful projects at https://lnkd.in/dde9yjCq #aisolutions #aihealthcare #healthcareinnovation

Kudos to AI in Precision Oncology editor Blythe Adamson, PhD, MPH, for her thoughtful and careful application of real-world evidence (RWE) to complement clinical trials. RWE plays a crucial role in addressing questions that traditional trials may not fully answer, particularly when utilizing large and diverse datasets. Blythe’s work underscores the importance of RWE in enhancing our understanding of treatment outcomes and patient care. Keep pushing forward, Blythe—excited to see the innovative solutions you bring to cancer research (and your manuscripts :)) Flatiron Health James Hamrick #CancerResearch #RealWorldEvidence #ClinicalTrials #OncologyInnovation

Now more than ever, improving the efficiency of #lungcancer screening is critical to improving patient survival rates. Check out this interesting article from AuntMinnie.com about the ability of risk-based lung cancer screening to mitigate racial and ethnic healthcare disparities and improve screening performance and efficiency compared to previous protocols. #MedTech #LungCancerScreening

Happy to share my latest article, "Evaluating digital health's role in cervical cancer screening: a health-economic model." In this piece, I briefly explore how digital technologies can revolutionize cervical cancer screening. Cervical cancer remains a pressing public health issue, with significant disparities in screening and treatment access contributing to its impact. The article delves into the potential economic benefits of digital health in cervical cancer screening and how achieving the WHO's 90-70-90 targets could yield a return of $3.20 for every dollar invested by 2050. It's a look at how innovation can drive not only healthcare efficiency but also broader societal and economic gains. #DigitalHealth #CervicalCancerScreening #PublicHealth #HealthEconomics #InnovationInHealthcare